There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...